Role of PET Scan in Diagnosis of Alzheimer's Disease: Evidence-Based Medicine
DOI:
https://doi.org/10.58445/rars.108Keywords:
Alzheimer's, PET Scan, Imaging, Dementia, ADAbstract
This is a review article focusing on how different forms and types of imaging are used in the diagnosis, identification, and treatment of Alzheimer's Disease. It will explain Alzheimer's Disease, its symptoms, and tests done to determine the condition. We then review different forms of imaging, (specifically PET Scan) what each of them accomplishes, how they are used, as well as the use and applications of biomarkers, as well as how biomarkers and imaging are used to determine AD out of all different types of Dementia, as well as the drugs used to treat the symptoms. Emphasis will be put on the treatment options available, including EMS and MRI.
References
Matthews, K. A., Xu, W., Gaglioti, A. H., Holt, J. B., Croft, J. B., Mack, D., & McGuire, L. C. (2018). Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015–2060) in adults aged≥ 65 years. Alzheimer’s & Dementia.
Chen Y, Sillaire AR, Dallongeville J, Skrobala E, Wallon D, Dubois B, Hannequin D, Pasquier F; Lille YOD study group. Low Prevalence and Clinical Effect of Vascular Risk Factors in Early-Onset Alzheimer's Disease. J Alzheimers Dis. 2017;60(3):1045-1054. doi: 10.3233/JAD-170367. PMID: 28984595; PMCID: PMC5676853.
Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010 Dec;7(8):656-64. doi: 10.2174/156720510793611592. PMID: 20678074; PMCID: PMC3090074.
Joachim CL, Morris JH, Selkoe DJ. Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases. Ann Neurol. 1988 Jul;24(1):50-6. doi: 10.1002/ana.410240110. PMID: 3415200.
Markowitsch HJ, Staniloiu A. Amnesic disorders. Lancet. 2012 Oct 20;380(9851):1429-40. doi: 10.1016/S0140-6736(11)61304-4. Epub 2012 Apr 13. PMID: 22503117.
Mortamais M, Ash JA, Harrison J, Kaye J, Kramer J, Randolph C, Pose C, Albala B, Ropacki M, Ritchie CW, Ritchie K. Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility. Alzheimers Dement. 2017 Apr;13(4):468-492. doi: 10.1016/j.jalz.2016.06.2365. Epub 2016 Oct 1. PMID: 27702618.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21. PMID: 21514250; PMCID: PMC3312024.
Stokholm J, Vogel A, Gade A, Waldemar G. Heterogeneity in executive impairment in patients with very mild Alzheimer's disease. Dement Geriatr Cogn Disord. 2006;22(1):54-9. doi: 10.1159/000093262. Epub 2006 May 8. PMID: 16682794.
Harwood DG, Sultzer DL, Feil D, Monserratt L, Freedman E, Mandelkern MA. Frontal lobe hypometabolism and impaired insight in Alzheimer disease. Am J Geriatr Psychiatry. 2005 Nov;13(11):934-41. doi: 10.1176/appi.ajgp.13.11.934. PMID: 16286436.
Barrett AM, Eslinger PJ, Ballentine NH, Heilman KM. Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects. Neurology. 2005 Feb 22;64(4):693-9. doi: 10.1212/01.WNL.0000151959.64379.1B. PMID: 15728294.
Parakh R, Roy E, Koo E, Black S. Pantomime and imitation of limb gestures in relation to the severity of Alzheimer's disease. Brain Cogn. 2004 Jul;55(2):272-4. doi: 10.1016/j.bandc.2004.02.049. PMID: 15177793.
Kato M, Meguro K, Sato M, Shimada Y, Yamazaki H, Saito H, Yamaguchi S, Yamadori A. Ideomotor apraxia in patients with Alzheimer disease: why do they use their body parts as objects? Neuropsychiatry Neuropsychol Behav Neurol. 2001 Jan;14(1):45-52. PMID: 11234908.
Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology--a bidirectional relationship. Nat Rev Neurol. 2014 Feb;10(2):115-9. doi: 10.1038/nrneurol.2013.269. Epub 2013 Dec 24. PMID: 24366271; PMCID: PMC3979317.
Rahayel S, Frasnelli J, Joubert S. The effect of Alzheimer's disease and Parkinson's disease on olfaction: a meta-analysis. Behav Brain Res. 2012 May 16;231(1):60-74. doi: 10.1016/j.bbr.2012.02.047. Epub 2012 Mar 5. PMID: 22414849.
Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer's disease. Neurology. 1986 Sep;36(9):1226-30. doi: 10.1212/wnl.36.9.1226. PMID: 3092131.
Portet F, Scarmeas N, Cosentino S, Helzner EP, Stern Y. Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study. Arch Neurol. 2009 Sep;66(9):1120-6. doi: 10.1001/archneurol.2009.196. PMID: 19752301; PMCID: PMC2896248.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. Erratum in: J Am Geriatr Soc. 2019 Sep;67(9):1991. PMID: 15817019.
Shaughnessy L, Sheard S, Goldfarb D, Atri A. Cognitive Assessment of Alzheimer's Disease and Dementias in Clinical Practice: Pragmatics of Brief Instruments and Neuropsychological Evaluation. J Clin Psychiatry. 2019 Jun 25;80(4):MS18002BR2C. doi: 10.4088/JCP.MS18002BR2C. PMID: 31237995.
Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment. F1000Res. 2018 Jul 31;7:F1000 Faculty Rev-1161. doi: 10.12688/f1000research.14506.1. PMID: 30135715; PMCID: PMC6073093.
Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010 Nov;5(6):463-6. doi: 10.1097/COH.0b013e32833ed177. PMID: 20978388; PMCID: PMC3078627.
Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol. 2011 Jan;29(1):26-32. doi: 10.1016/j.tibtech.2010.09.007. Epub 2010 Oct 23. PMID: 20971518; PMCID: PMC3016495.
Bateman RJ, Barthélemy NR, Horie K. Another step forward in blood-based diagnostics for Alzheimer's disease. Nat Med. 2020 Mar;26(3):314-316. doi: 10.1038/s41591-020-0797-4. PMID: 32132715.
Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H, Blennow K, Reiman EM, Stomrud E, Dage JL, Hansson O. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 2020 Mar;26(3):379-386. doi: 10.1038/s41591-020-0755-1. Epub 2020 Mar 2. PMID: 32123385.
Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, Bourakova V, Cobigo Y, Heuer H, Spina S, VandeVrede L, Chai X, Proctor NK, Airey DC, Shcherbinin S, Duggan Evans C, Sims JR, Zetterberg H, Blennow K, Karydas AM, Teunissen CE, Kramer JH, Grinberg LT, Seeley WW, Rosen H, Boeve BF, Miller BL, Rabinovici GD, Dage JL, Rojas JC, Boxer AL; Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med. 2020 Mar;26(3):387-397. doi: 10.1038/s41591-020-0762-2. Epub 2020 Mar 2. PMID: 32123386; PMCID: PMC7101073.
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30;367(9):795-804. doi: 10.1056/NEJMoa1202753. Epub 2012 Jul 11. Erratum in: N Engl J Med. 2012 Aug 23;367(8):780. PMID: 22784036; PMCID: PMC3474597.
Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med. 2018 Dec;284(6):643-663. doi: 10.1111/joim.12816. Epub 2018 Aug 19. PMID: 30051512.
Pawlowski M, Meuth SG, Duning T. Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside. Diagnostics (Basel). 2017 Jul 13;7(3):42. doi: 10.3390/diagnostics7030042. PMID: 28703785; PMCID: PMC5617942.
Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14052-7. doi: 10.1073/pnas.0805902105. Epub 2008 Sep 8. PMID: 18779561; PMCID: PMC2544577.
Nabers A, Perna L, Lange J, Mons U, Schartner J, Güldenhaupt J, Saum KU, Janelidze S, Holleczek B, Rujescu D, Hansson O, Gerwert K, Brenner H. Amyloid blood biomarker detects Alzheimer's disease. EMBO Mol Med. 2018 May;10(5):e8763. doi: 10.15252/emmm.201708763. PMID: 29626112; PMCID: PMC5938617.
Brosseron F, Traschütz A, Widmann CN, Kummer MP, Tacik P, Santarelli F, Jessen F, Heneka MT. Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer's disease. Alzheimers Res Ther. 2018 Feb 26;10(1):25. doi: 10.1186/s13195-018-0353-3. PMID: 29482610; PMCID: PMC5828084.
Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004 May;24(5):806-15. doi: 10.1161/01.ATV.0000120374.59826.1b. Epub 2004 Feb 5. PMID: 14764421.
Cermenati G, Mitro N, Audano M, Melcangi RC, Crestani M, De Fabiani E, Caruso D. Lipids in the nervous system: from biochemistry and molecular biology to patho-physiology. Biochim Biophys Acta. 2015 Jan;1851(1):51-60. doi: 10.1016/j.bbalip.2014.08.011. Epub 2014 Aug 20. PMID: 25150974.
Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med. 2012 Apr;2(4):a006213. doi: 10.1101/cshperspect.a006213. PMID: 22474610; PMCID: PMC3312396.
Fantoni ER, Chalkidou A, O' Brien JT, Farrar G, Hammers A. A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer's Disease. J Alzheimers Dis. 2018;63(2):783-796. doi: 10.3233/JAD-171093. PMID: 29689725; PMCID: PMC5929301.
Ferreira LK, Busatto GF. Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications. Clinics (Sao Paulo). 2011;66 Suppl 1(Suppl 1):19-24. doi: 10.1590/s1807-59322011001300003. PMID: 21779719; PMCID: PMC3118433.
Ding Y, Sohn JH, Kawczynski MG, Trivedi H, Harnish R, Jenkins NW, Lituiev D, Copeland TP, Aboian MS, Mari Aparici C, Behr SC, Flavell RR, Huang SY, Zalocusky KA, Nardo L, Seo Y, Hawkins RA, Hernandez Pampaloni M, Hadley D, Franc BL. A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using 18F-FDG PET of the Brain. Radiology. 2019 Feb;290(2):456-464. doi: 10.1148/radiol.2018180958. Epub 2018 Nov 6. PMID: 30398430; PMCID: PMC6358051.
Radiological Society of North America. Artificial intelligence predicts Alzheimer's years before diagnosis, 181106104249.
De Brito Sanchez, R.; de Barros, L.; Rodrigues, S.C.M.; Fernandes, J.C.L.; Bondioli, A.C.V.; de Campos Mundin, H.A.; de Sousa, V.D.S.; da Silva, L.H.B.O. Artificial Intelligence to Detect Alzheimer’s in Magnetic Resonances, IFMBE Proceedings of the XXVI Brazilian Congress on Biomedical Engineering; Costa-Felix, R.; Machado, J.; Alvarenga, A. (eds), Singapore, 2019, 70/2, pp. 59-63.
Graham S, Depp C, Lee EE, Nebeker C, Tu X, Kim HC, Jeste DV. Artificial Intelligence for Mental Health and Mental Illnesses: an Overview. Curr Psychiatry Rep. 2019 Nov 7;21(11):116. doi: 10.1007/s11920-019-1094-0. PMID: 31701320; PMCID: PMC7274446.
McEvoy LK, Fennema-Notestine C, Roddey JC, Hagler DJ Jr, Holland D, Karow DS, Pung CJ, Brewer JB, Dale AM; Alzheimer's Disease Neuroimaging Initiative. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology. 2009 Apr;251(1):195-205. doi: 10.1148/radiol.2511080924. Epub 2009 Feb 6. PMID: 19201945; PMCID: PMC2663582.
Frisoni GB, Laakso MP, Beltramello A, Geroldi C, Bianchetti A, Soininen H, Trabucchi M. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease. Neurology. 1999 Jan 1;52(1):91-100. doi: 10.1212/wnl.52.1.91. PMID: 9921854.
Lu PH, Mendez MF, Lee GJ, Leow AD, Lee HW, Shapira J, Jimenez E, Boeve BB, Caselli RJ, Graff-Radford NR, Jack CR, Kramer JH, Miller BL, Bartzokis G, Thompson PM, Knopman DS. Patterns of brain atrophy in clinical variants of frontotemporal lobar degeneration. Dement Geriatr Cogn Disord. 2013;35(1-2):34-50. doi: 10.1159/000345523. Epub 2013 Jan 9. PMID: 23306166; PMCID: PMC3609420.
Apostolova LG, Green AE, Babakchanian S, Hwang KS, Chou YY, Toga AW, Thompson PM. Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer Disease. Alzheimer Dis Assoc Disord. 2012 Jan-Mar;26(1):17-27. doi: 10.1097/WAD.0b013e3182163b62. PMID: 22343374; PMCID: PMC3286134.
Nafisi-Moghadam R, Rahimdel A, Shanbehzadeh T, Fallah R. Comparison of Diffuse Weighted Imaging and Fluid Attenuation Inversion Recovery Sequences of MRI in Brain Multiple Sclerosis Plaques Detection. Iran J Child Neurol. 2017 Winter;11(1):13-20. PMID: 28277551; PMCID: PMC5329755.
Koo DL, Jeong HG, Nam H. Thalamic hyperintensity on diffusion-weighted MRI in a patient with nonconvulsive status epilepticus. J Epilepsy Res. 2013 Jun 30;3(1):32-4. doi: 10.14581/jer.13006. PMID: 24649469; PMCID: PMC3957314.
Felix-Morais R, Andrade LC, Rebelo O. Creutzfeldt-Jakob disease: typical imaging findings. BMJ Case Rep. 2014 Mar 28;2014:bcr2014203997. doi: 10.1136/bcr-2014-203997. PMID: 24682142; PMCID: PMC3975535.
Kwan LT, Reed BR, Eberling JL, Schuff N, Tanabe J, Norman D, Weiner MW, Jagust WJ. Effects of subcortical cerebral infarction on cortical glucose metabolism and cognitive function. Arch Neurol. 1999 Jul;56(7):809-14. doi: 10.1001/archneur.56.7.809. PMID: 10404982; PMCID: PMC2733358.
Kumar D, Vipin A, Wong B, Ng KP, Kandiah N. Differential Effects of Confluent and Nonconfluent White Matter Hyperintensities on Functional Connectivity in Mild Cognitive Impairment. Brain Connect. 2020 Dec;10(10):547-554. doi: 10.1089/brain.2020.0784. Epub 2020 Nov 16. PMID: 33050714.
Manoochehri M, Huey ED. Diagnosis and management of behavioral issues in frontotemporal dementia. Curr Neurol Neurosci Rep. 2012 Oct;12(5):528-36. doi: 10.1007/s11910-012-0302-7. PMID: 22847063; PMCID: PMC3443960.
McFarland NR. Diagnostic Approach to Atypical Parkinsonian Syndromes. Continuum (Minneap Minn). 2016 Aug;22(4 Movement Disorders):1117-42. doi: 10.1212/CON.0000000000000348. PMID: 27495201; PMCID: PMC5567217.
Teeple RC, Caplan JP, Stern TA. Visual hallucinations: differential diagnosis and treatment. Prim Care Companion J Clin Psychiatry. 2009;11(1):26-32. doi: 10.4088/pcc.08r00673. PMID: 19333408; PMCID: PMC2660156.
Brown RG, Landau S, Hindle JV, Playfer J, Samuel M, Wilson KC, Hurt CS, Anderson RJ, Carnell J, Dickinson L, Gibson G, van Schaick R, Sellwood K, Thomas BA, Burn DJ; PROMS-PD Study Group. Depression and anxiety related subtypes in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):803-9. doi: 10.1136/jnnp.2010.213652. Epub 2011 Jan 8. PMID: 21217155.
Shiner E, Taylor L, Mohan A, Watson S, Sachdev PS. Severe depression masquerading as Creutzfeldt-Jakob disease. BMJ Case Rep. 2014 Apr 19;2014:bcr2013203352. doi: 10.1136/bcr-2013-203352. PMID: 24748140; PMCID: PMC3992591.
Tiel C, Sudo FK, Alves GS, Ericeira-Valente L, Moreira DM, Laks J, Engelhardt E. Neuropsychiatric symptoms in Vascular Cognitive Impairment: a systematic review. Dement Neuropsychol. 2015 Jul-Sep;9(3):230-236. doi: 10.1590/1980-57642015DN93000004. PMID: 29213966; PMCID: PMC5619363.
Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012 May 7;3:73. doi: 10.3389/fneur.2012.00073. PMID: 22586419; PMCID: PMC3345875.
Seeley WW, Miller BL. Alzheimer's disease and other dementias. In: Hauser SL, ed. Harrison's Neurology in Clinical Medicine. 3rd edition. New York: McGraw-Hill Medical; 2013.
Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer's disease: Targeting the Cholinergic System. Curr Neuropharmacol. 2016;14(1):101-15. doi: 10.2174/1570159x13666150716165726. PMID: 26813123; PMCID: PMC4787279.
Cheng YJ, Lin CH, Lane HY. Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer's Disease. Int J Mol Sci. 2021 Feb 25;22(5):2283. doi: 10.3390/ijms22052283. PMID: 33668976; PMCID: PMC7956475.
Fish, P.V.; Steadman, D.; Bayle, E.D.; Whiting, P. New approaches for the treatment of Alzheimer’s disease. Bioorg. Med. Chem. Lett., 2019, 29(2), 125-133.
U.S. Food and drug administration. FDA consumer health information, https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm519875 .html
U.S. Food and drug administration. Early Alzheimer’s disease: Developing Drugs for Treatment Guidance for Industry, https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegul atoryInformation/Guidances/UCM596728.pdf
Rajasekhar K, Mehta K, Govindaraju T. Hybrid Multifunctional Modulators Inhibit Multifaceted Aβ Toxicity and Prevent Mitochondrial Damage. ACS Chem Neurosci. 2018 Jun 20;9(6):1432-1440. doi: 10.1021/acschemneuro.8b00033. Epub 2018 Mar 28. PMID: 29557650.
Rahmanian, M.; Mosalanejad, L.; Abdolallahifard, S. An Alzheimer’s Intelligence Care System (AICS) to assist Alzheimer’s Patients : Design and development of application. J. Res. Med. Dental. Sci, 2018, 6(6), 9-15.
Fabrizio C, Termine A, Caltagirone C, Sancesario G. Artificial Intelligence for Alzheimer's Disease: Promise or Challenge? Diagnostics (Basel). 2021 Aug 14;11(8):1473. doi: 10.3390/diagnostics11081473. PMID: 34441407; PMCID: PMC8391160.
How Will Artificial Intelligence Impact Alzheimer’s Research? https://labiotech.eu/features/artificial-intelligence-alzheimer
Downloads
Posted
Categories
License
Copyright (c) 2023 Dyuti Venkat
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.